Isomorphic Labs
AI-driven drug discovery spinoff from DeepMind using AlphaFold to discover novel medicines.
About
Isomorphic Labs, founded by Demis Hassabis (DeepMind CEO/Alphabet), applies AlphaFold technology to drug discovery. Partnerships with Eli Lilly and Novartis. Raised $600M Series A in 2025. Teams look it up for Drug Discovery, Biotechnology, AI-Driven Drug Discovery.
Frequently asked
What does Isomorphic Labs do?
Isomorphic Labs is a Drug Discovery company that offers Platform / Partnership. Teams look it up for Biotechnology, AI-Driven Drug Discovery, Foundation Model. It is based in London, United Kingdom and was founded in 2021. Public records show $4.7B in total funding. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has Isomorphic Labs raised?
Isomorphic Labs has raised a total of $4.7B in funding. The most recent round on record is Funding Round.
Where is Isomorphic Labs headquartered?
Isomorphic Labs is headquartered in London, United Kingdom.
When was Isomorphic Labs founded?
Isomorphic Labs was founded in 2021.
What industry does Isomorphic Labs operate in?
Isomorphic Labs operates in Drug Discovery, Biotechnology, AI-Driven Drug Discovery, Foundation Model, Generative AI.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.